The QualityStocks Daily Monday, August 5th, 2024

Today's Top 3 Investment Newsletters

Premium Stock Alerts(INDO) $3.6700 +60.26%

Schaeffer's(UVXY) $61.7700 +58.30%

QualityStocks(BTCY) $0.6600 +42.52%

The QualityStocks Daily Stock List

Greene Concepts (INKW)

QualityStocks, MarketClub Analysis, PennyTrader, Penny Picks, HotOTC, Damn Good Penny Picks, Wall Street Mover, PREPUMP STOCKS, Penny Stock Newsletter, MicroCapDaily and MegaPennyStocks reported earlier on Greene Concepts (INKW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Greene Concepts, Inc. (OTC: INKW) manages a beverage and bottling firm in Marion, North Carolina through Mammoth Ventures Inc., its wholly-owned subsidiary.

The company is based in Clovis, California and was founded in 1952, on August 18th by Leonard M. Greene. Its product line is made up of enhanced athletic drinks, beverage offerings, artesian and spring water as well as ketogenic and CBD-infused beverages. The company is focused on delivering water to its consumers directly.

Its Marion plant is a 60,000 ft2 bottling and beverage facility that is found within the Pisgah National Forest boundaries. The plant’s water source is a combination of 7 artesian and spring wells that are fed from a natural aquifer found in the Pisgah forest. Mammoth Ventures is also a 3rd party bottler and producer of ‘white label’ water and beverage products. These services are offered to clients that would like to market their own product formulations, labeling and brand name while outsourcing the bottling and production of their products to Mammoth. Through its Water Club Inc. subsidiary, the company is pursuing subscription-based delivery of scientifically formulated beverages and water directly to the consumer’s markets and homes.

The firm recently hired an auditing company to audit its financials, in preparation for an up list to the NASDAQ. This could not only lead to a change in its stock symbol but also attract more investors, which will boost both the firm’s share prices as well as its growth.

Greene Concepts (INKW), closed Monday's trading session at $0.003, up 76.4706%, on 73,861,654 volume. The average volume for the last 3 months is 78,601 and the stock's 52-week low/high is $0.0014/$0.0079.

Biotricity Inc. (BTCY)

QualityStocks, MarketBeat, Fierce Analyst, Small Cap Firm, StockWireNews, StockStreetWire, Broad Street, SmallCap Network, AwesomeStocks, TradersPro, Insider Financial, PoliticsAndMyPortfolio, SECFilings.com News, RedChip, Awareness Stocks, Wealth Insider Alert, MarketClub Analysis, SmallCapNetwork, InvestorPlace, Stock News Now, StocksEarning, The Online Investor and Wall Street Mover reported earlier on Biotricity Inc. (BTCY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Biotricity Inc. (NASDAQ: BTCY) is a medical technology firm that is engaged in the provision of biometric data monitoring solutions to the medical and consumer markets.

The firm has its headquarters in Redwood City, California and was incorporated in 2012, on August 29th by Peter McGldrick and Waqaas Al-Siddiq. It serves consumers in Canada and the United States.

The company’s research and development division is focused on the preventive healthcare market. Its vision is to put health management into the hands of every patient by providing diagnostic and post-diagnostic solutions for chronic and lifestyle ailments.

The enterprise’s products include its mobile cardiac telemetry device, known as Bioflux, which is an integrated electrocardiogram device and software solution that offers real-time transmission and monitoring of an individual’s ECG information. This device can also detect arrhythmias. It also produces Biocare health and a personal heart monitor known as Bioheart. In addition to this, it offers a virtual clinic platform known as Biocare Telemed, which allows physicians to offer patient care remotely. Furthermore, the enterprise is expanding medical-grade monitoring into the consumer market through its Biolife solution, which helps users to manage chronic conditions. This health and lifestyle solution is made up of a device that monitors an individual’s heart-rhythm, physical activity, temperature, calories and respiration, among other things.

The company recently announced that it would be releasing its Biocare Cardiac application for people at risk of or with cardiovascular disease. The application has been designed for use with the Galaxy Watch4 series by Samsung. This partnership and the application’s launch not only helps cardiovascular patients to take control of their condition but also extend the firm’s consumer reach, which will have a positive impact on the company’s growth and investments.

Biotricity Inc. (BTCY), closed Monday's trading session at $0.66, up 42.5178%, on 321,495 volume. The average volume for the last 3 months is 27,490 and the stock's 52-week low/high is $0.38/$2.7605.

Finch Therapeutics (FNCH)

QualityStocks, MarketBeat and FreeRealTime reported earlier on Finch Therapeutics (FNCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Finch Therapeutics Group Inc. (NASDAQ: FNCH) is a clinical-stage microbiome therapeutics firm that is focused on the development of new orally administered biological medications for the treatment of various indications.

The firm has its headquarters in Somerville, Massachusetts and was incorporated in 2014 by Zain Kassam, Tom Borody, Andrew Noh and Mark Smith. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is party to collaboration and license agreements with the University of Minnesota; Skysong Innovations LLC; and Takeda Pharmaceutical Company Ltd. It is focused on delivering microbial therapies to patients with unmet medical needs.

The enterprise’s product pipeline is comprised of orally administered formulations, FIN-525 and TAK-524, which target consortia product candidates for the treatment of Crohn’s disease and ulcerative colitis. It also develops an enriched consortia formulation which is orally administered and is dubbed FIN-211, to help treat autism spectrum disorder. In addition to this, the enterprise is involved in the development of an orally administered microbiome capsule known as CP101, which is undergoing phase III clinical trials for the treatment of chronic Hepatitis B virus. This formulation is also being developed for the treatment of Clostridioides difficile infection.

The firm is currently focused on executing its strategic objectives, which include advancing its Autism spectrum disorder and Clostridioides difficile infection programs. The success of these programs will help deliver on the firm’s mission to serve patients. This is in addition to boosting the firm’s revenues and benefiting its shareholders.

Finch Therapeutics (FNCH), closed Monday's trading session at $2.59, up 29.5%, on 69,283 volume. The average volume for the last 3 months is 25,390 and the stock's 52-week low/high is $0.80/$7.99.

Koil Energy Solutions (KLNG)

We reported earlier on Koil Energy Solutions (KLNG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Koil Energy Solutions Inc. (OTCQB: KLNG) is an energy services firm engaged in the provision of equipment and support services to the energy and offshore industries.

The firm has its headquarters in Houston, Texas and was incorporated in 1997 by Ronald E. Smith and Mary L. Budrunas. Prior to its name change in April 2022, the firm was known as Deep Down Inc. It operates as part of the oil and gas equipment and services industry, under the energy sector. The firm serves consumers across the globe.

The enterprise provides connection and termination operations services; engineering and project management services, including the design, installation, and retrieval of subsea equipment and systems; construction support services; and well-commissioning services. It also offers spooling; project management and engineering; storage management; testing and commissioning; and refurbishment and repurposing of recovered subsea equipment, as well as support services for offshore interventions. In addition to this, the enterprise offers loose steel tube flying lead and umbilical hardware products, as well as riser isolation valves and subsea isolation valve services. Further, it offers installation aids, including lay chutes, flying lead installation systems, tensioners, mud mats, buoyancy modules, clump weights, under-rollers, pumping and testing skids, control booths, fluid drum carriers, carousels and running and parking deployment frames, among others. The enterprise serves energy companies, subsea equipment manufacturers, engineering and construction firms, subsea equipment installation contractors, offshore drilling contractors and other firms involved in maritime operations.

The company recently released its latest financial results, with its CEO noting that they remained focused on growing the business and positioning the firm better for further success in the renewable energy segments.

Koil Energy Solutions (KLNG), closed Monday's trading session at $1.26, up 24.7525%, on 347,545 volume. The average volume for the last 3 months is 34,382 and the stock's 52-week low/high is $0.42/$1.40.

Beasley Broadcast Group (BBGI)

The Online Investor, MarketBeat, StreetInsider, InvestorPlace, Marketbeat.com, Wall Street Resources, TraderPower, StockHotTips, StockEarnings, SmallCapInvestor.com and QualityStocks reported earlier on Beasley Broadcast Group (BBGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Beasley Broadcast Group Inc. (NASDAQ: BBGI) (FRA: BZS) is a radio broadcasting firm that is focused on the operation of radio stations.

The firm has its headquarters in Naples, Florida and was incorporated in 1961 by George G. Beasley. It serves consumers in the United States.

The company’s main source of revenue is the sale of advertising. Its subsidiaries include Team Renegades LLC, Renegades Holdings Inc., OutlawsXP Inc., Beasley Media Group Licenses LLC, Beasley Media Group and Beasley Mezzanine Holdings LLC.

The enterprise operates and owns AM and FM radio stations in mid-sized and large markets. These markets include West Palm Beach-Boca Raton and Miami-Fort Lauderdale in Florida; Tampa-Saint Petersburg; Philadelphia in Panama; Las Vegas in Nevada; Greenville-New Bern-Jacksonville and Fayetteville in New Caledonia; Fort Myers-Naples; Charlotte; Boston in Morocco; Morristown; Augustaand Atlanta in Gabon; and Wilmington in Germany. It offers management services to 2 radio stations in Las Vegas, Nevada. The enterprise also offers digital marketing and advertising solutions across the U.S. via its radio broadcast and digital operations. In addition to this, it provides national and local advertisers integrated marketing solutions across event, digital and audio platforms. Furthermore, the enterprise operates an e-sports team known as Houston Outlaws, which competes in the Overwatch League.

The firm recently announced its latest financial results which show significant increases in its net revenues and healthy growth in Wilmington, Tampa, Philadelphia, New Jersey, Las Vegas, Atlanta, Boston and Detroit, among others. Currently, it is focused on building its e-sports portfolio and looking for new ways to drive profitable long-term revenue growth.

Beasley Broadcast Group (BBGI), closed Monday's trading session at $0.5969, up 24.0956%, on 766,500 volume. The average volume for the last 3 months is 68,870 and the stock's 52-week low/high is $0.4224/$1.28.

Aileron Therapeutics (ALRN)

TradersPro, QualityStocks, MarketBeat, StreetInsider, InvestorPlace, BUYINS.NET, WiseAlerts, The Online Investor, StockMarketWatch, Money Wealth Matters and Barchart reported earlier on Aileron Therapeutics (ALRN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aileron Therapeutics Inc. (NASDAQ: ALRN) (FRA: O15) is a clinical stage biopharmaceutical firm that is engaged in developing and commercializing a new class of therapeutics to help treat myelodysplastic syndrome, acute myeloid leukemia, cancer and other ailments.

Aileron Therapeutics Inc. is based in Watertown, Massachusetts and was incorporated in 2001 by Loren David Walensky, Joseph A. Yanchik III, Huw M. Nash, Rosana Kapeller and Gregory L. Verdine. Before changing its name in February 2007, the firm was known as Renegade Therapeutics Inc.

Aileron Therapeutics serves consumers in the United States and is party to a collaboration agreement with Pfizer to assess the combination of IBRANCE and ALRN-6924 in MDM2-amplified cancers and another with DANA-Farber/Boston Children’s Cancer and Blood Disorders Center for a multi-center, open-label, pediatric phase I ALRN-6924 clinical trial.

The Aileron Therapeutics Inc. product portfolio includes a peptide that permeates cells and reactivates tumor suppression in p53 cancers that are not mutated. The product called ALRN-6924, is currently undergoing a phase 1b clinical trial to test a combination of cytarabine and ALRN-6924 in patients with myelodysplastic syndromes; phase 1 clinical trial to evaluate its efficacy in treating advance myelodysplastic syndrome and acute myeloid leukemia; a phase 2a clinical trial for peripheral T-cell lymphoma and a phase 2a clinical trial to test its effectiveness in treating advanced solid tumors.

Aileron Therapeutics Inc. recently reported that data from the phase 1b study conducted on its ALRN-6924 candidate, which assesses its potential as a therapeutic agent that prevents chemotherapy-induced toxicities, may be used to improve the tolerance for chemotherapy for many cancer patients as well as better their quality of life.

Aileron Therapeutics (ALRN), closed Monday's trading session at $2.25, up 9.7561%, on 62,331 volume. The average volume for the last 3 months is 1.685M and the stock's 52-week low/high is $1.01/$7.42.

New Oriental Education & Technology Group (EDU)

StocksEarning, MarketClub Analysis, Schaeffer's, StockEarnings, MarketBeat, InvestorPlace, StreetInsider, TradersPro, Zacks, Daily Trade Alert, Marketbeat.com, Trades Of The Day, INO.com Market Report, FreeRealTime, QualityStocks, SmarTrend Newsletters, Uncommon Wisdom, Street Insider, InvestmentHouse, Hit and Run Candle Sticks, Kiplinger Today, The Street, China Vesting, TheStockAdvisors, Weekly Market Strategies, Sling-Shot-Stocks, Wealth Insider Alert, MarketDNA, Cabot Wealth, Leeb's Market Forecast, AllPennyStocks, TopStockAnalysts, The Complete Investor, ChartPoppers, Investing Lab, Greenbackers, DrStockPick, CRWEWallStreet, Princeton Research, CRWEPicks, CRWEFinance, ChartAdvisor, BUYINS.NET, BestOtc, Barchart, Daily Market Beat, Stock Tips Network, VectorVest, TradingMarkets, Trading Markets, Top Secret Stocks, Top Pros' Top Picks, The Online Investor, The Best Newsletters, StreetAuthority Daily, PennyOmega, StockHotTips, Investopedia, Smart Investing Society, Short Term Wealth, PROFIT CONFIDENTIAL, PennyToBuck, Penny Sleuth, Money Morning, Millennium-Traders, Investor Ideas and StockMarketWatch reported earlier on New Oriental Education & Technology Group (EDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New Oriental Education & Technology Group Inc. (NYSE: EDU) (FRA: N1U) (HKG: 9901) (BMV: EDUN) is engaged in the provision of private educational services under the New Oriental brand.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 1993, on November 16th by Yong Qiang Qian and Min Hong Yu. It operates as part of the consumer discretionary industry, under the consumer services sub-industry.

The company operates through the Test Preparation and other courses, K-12 AST and Others segments. It has over 500 firms in its corporate family and mainly serves consumers in China.

The enterprise provides test preparation courses to students who will be taking entrance and language exams used by learning institutions in Commonwealth countries, China and the U.S., as well as after-school tutoring courses for high school and middle school students that help boost exam scores. It also provides online education programs that include pre-school, K-12 and college education; develops and also edits educational materials for test preparation and language training; operates a full-time private secondary and primary school in Yangzhou; and offers language training courses for English and other foreign languages like Spanish, Italian, Korean, French, Japanese and German. In addition to this, the enterprise also provides overseas study tour services and overseas studies consulting services.

As of May 2020, the company offered its programs and services to over 1300 learning centers and 100+ schools. It is focused on expanding to new regions, which will extend its consumer reach and boost its growth, which will encourage more investments into the firm.

New Oriental Education & Technology Group (EDU), closed Monday's trading session at $65.27, up 8.8922%, on 3,241,582 volume. The average volume for the last 3 months is 17,258 and the stock's 52-week low/high is $49.94/$98.20.

comScore Inc. (SCOR)

MarketBeat, StreetInsider, The Street, Street Insider, QualityStocks, InvestorPlace, Zacks, Daily Trade Alert, Barchart, The Motley Fool, MarketClub Analysis, Louis Navellier, internetnews, internet, Hit and Run Candle Sticks, BUYINS.NET, BestChartNow, InsiderTrades, AllPennyStocks, Money Morning, Penny Stock Buzz, Schaeffer's, SmarTrend Newsletters, StockMarketWatch, StreetAuthority Daily, The Stock Dork, TradersPro and Marketbeat.com reported earlier on comScore Inc. (SCOR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

comScore, Inc. (NASDAQ: SCOR) is an information and analytics firm that measures audiences, consumer behavior and advertising across media platforms.

The firm has its headquarters in Reston, Virginia and was incorporated in August 1999 by Gian Mark Flugoni and Magid M. Abraham. It serves consumers around the globe.

The company helps measure what individuals do as they interact with the digital world across various technology platforms and devices, such as desktop computers, televisions, tablets and smartphones. Its objective is to help clients monetize audiences globally. The company serves technology providers, agencies, brand advertisers, content owners, movie studios, television networks and digital publishers.

The enterprise provides ratings and planning services and products that include the Plan Metrix, which provides understanding of consumer lifestyle; the Video Metrix, which measures digital video consumption; and the Mobile and Media Multi-Platform Metrix, which measures apps and websites on tablets, smartphones and computers. Other ratings and planning products include the Total Home Panel Suite, which captures connected TV, OTT and IOT content consumption and device usage; and the comScore Campaign Ratings for verification of desktop and mobile video campaigns. In addition to this, the enterprise also provides analytics and optimization services and products that offer solutions for evaluation, optimization and planning of advertising campaigns.

The company recently entered into a new agreement with Cornerstone Media Group. Cornerstone intends to expand its offering to the local market space through the exclusive use of comScore’s TV ratings currency data. This move will bring in additional revenue into the company and help grow its consumer reach, which will be good for the company’s growth.

comScore Inc. (SCOR), closed Monday's trading session at $12.95, up 7.9167%, on 25,026 volume. The average volume for the last 3 months is 135,264 and the stock's 52-week low/high is $9.60/$20.9691.

NeuroOne Medical Technologies (NMTC)

QualityStocks, Small Cap Firm, Fierce Analyst, StockWireNews, StockStreetWire, PCG Advisory, Jeff Bishop, Wolf of Penny Stocks, TopPennyStockMovers, Small Caps, MarketClub Analysis, MarketBeat, Make Penny Stocks Great Again, Epic Stock Picks and Awareness Stocks reported earlier on NeuroOne Medical Technologies (NMTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology firm that is engaged in developing and commercializing film electrode technology for sEEG and cEEG recording, ablation, brain stimulation and spinal cord stimulation solutions for patients with neurological disorders.

The firm has its headquarters in Eden Prairie, Minnesota and was incorporated in 2009, on August 20th. Prior to its name change, the firm was known as Original Source Entertainment Inc. It serves consumers in the U.S.

The company values methodical research, quality work and is party to various lasting collaborations with leading experts in its field. It has an experienced management team and has assembled impressive AI and scientific advisory boards.

The enterprise is committed to offering high-definition and minimally invasive solutions for patients with various disorders. Its thin film electrode technology allows for higher density contacts, which increases signal acquisition and mapping resolution. The enterprise’s technology is made up of three main types of cortical electrodes namely, dual-sided electrodes, strip electrodes and grid electrodes. The technology is used for sEEG (stereoelectroencephalography) and cEEG (electroencephalogram) recordings for patients suffering from dystonia, essential tremors, Parkinson’s disease, epilepsy and chronic pain caused by failed surgeries. The technology decreases procedural costs and improves patient outcomes.

The firm recently entered into a strategic partnership agreement with RBC Medical Innovations, which entails the development and manufacture of a radiofrequency generator. This move will allow the firm to fully participate in the growing market, which may encourage more investments into the firm and boost the firm’s growth.

NeuroOne Medical Technologies (NMTC), closed Monday's trading session at $0.71, up 7.2508%, on 158,580 volume. The average volume for the last 3 months is 406 and the stock's 52-week low/high is $0.602/$2.00.

Akeso Inc. (AKESF)

We reported earlier on Akeso Inc. (AKESF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Akeso Inc. (OTC: AKESF) (HKG: 9926) (FRA: 4RY) is a biopharmaceutical firm focused on researching, developing, manufacturing, and commercializing antibody drugs.

The firm has its headquarters in Zhonshan, China and was incorporated in 2012. It operates as part of the biotechnology industry, under the healthcare sector. The firm mainly serves consumers in the People’s Republic of China.

Akeso is party to collaboration agreements with AstraZeneca Pharmaceuticals; Pfizer Pharmaceuticals; Shenzhen Chipscreen Biosciences Company Limited; and Summit Therapeutics Inc.

The enterprise develops AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors; AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis; and AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors. It also develops AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors; AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; and AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis. In addition to this, it develops AK115, a NGF monoclonal antibody; AK127, a TIGIT monoclonal antibody to treat solid tumors; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

The firm recently announced that the supplemental biologics license application (sBLA) for its Ivonescimab injection was recently accepted by the China National Medical Products Administration. This move brings them closer to making this a new standard of care treatment option for both first line and second-line lung cancer therapy; a feat that will positively influence investments into the firm.

Akeso Inc. (AKESF), closed Monday's trading session at $5.719, even for the day. The average volume for the last 3 months is 8.522M and the stock's 52-week low/high is $4.30/$6.45.

Coinbase Global Inc. (COIN)

Schaeffer's, InvestorPlace, QualityStocks, MarketClub Analysis, The Street, Zacks, Prfmonline, MarketBeat, Greenbackers, Early Bird, StockEarnings, Kiplinger Today, INO Market Report, Investopedia, OTCPicks, SmallCapVoice, The Online Investor, Ceocast News, The Wealth Report, InsiderTrades, HotOTC, CoolPennyStocks, Daily Trade Alert, Trades Of The Day, StocksEarning, StockEgg, Penny Invest, Stock Stars, TradersPro, Stock Rich, FreeRealTime, CryptoCurrencyWire, Top Pros' Top Picks, BestOtc, The Stock Psycho, Top Gun, CNBC Breaking News, BullRally, HotShotStocks, Investors Underground, Wealth Daily, StockHotTips, BillionDollarClub, Smartmoneytrading, bullseyeoptiontrading, FeedBlitz, Cabot Wealth, Jeff Bishop, Today's Financial News, Eagle Financial Publications, Energy and Capital, MadPennyStocks, Stockpalooza, Summa Money, StockRich, PennyInvest, PennyStockVille, PennyTrader Publisher, MarketClub Options, Louis Navellier, Profit Confidential, DividendStocks, Dawn Report, AlphaShark Trading, Atomic Trades, wealthmintrplus, Stock Fortune Teller, WiseAlerts, wyatt research newsletter, Blaque Capital Stocks, BloomMoney, CRWEWallStreet, Standout Stocks, Round Up the Bulls, StockMister, Pennybuster, Penny Stock Rumble, AllPennyStocks, Momentum Traders, MicrocapVoice, TradingPub, InvestorsUnderground, Dynamic Wealth Report, Penny Stock Finder, Stock Traders Chat, Trading with Larry Benedict, Green Chip Stocks, Stock Analyzer, Early Investing, Wealth Whisperer and TipRanks reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As Coinbase Global Inc. (NASDAQ: COIN) gears up to unveil its second quarter (Q2) 2024 earnings report this week after the U.S. market closes, anticipation is building among market watchers and cryptocurrency enthusiasts. Given the company’s pivotal role in the digital currency space, expectations are high for the company to continue its impressive performance.

So, what should you watch out for now that the countdown has begun?

Coinbase’s revenue for Q2 is projected to nearly double to $1.4 billion, up from $708 million in the previous quarter, making this the fourth consecutive quarter of positive revenue performance. This surge will be primarily fueled by a more than twofold increase in transaction revenue, which is projected to reach $846 million.

Earnings per share (EPS) are expected to reach $0.94, which marks an all-time high in the third consecutive quarter of profitability and signals a momentous transformation away from the previous era of losses. Investors will keep an eye on these figures to determine Coinbase’s financial health and growth momentum.

The company’s financial performance is linked to the broader cryptocurrency market. Recent developments have affected the crypto market. The market has experienced heightened activity as a result of the swift rise in spot Bitcoin ETFs, which received U.S. Security Exchange Commisson approval at the start of the year. What’s more, Bitcoin and Ethereum prices have shown impressive resilience, rising 54% and 43% respectively in 2024.

Another significant milestone in Coinbase’s outlook is the regulatory and potential influence of political figures. During a conference in Nashville, Tennessee, this past weekend, former President Donald Trump stated that, after winning the presidential election, he intends to turn the United States into a “crypto capital of the planet.” Trump has outlined plans to set up a presidential advisory council dedicated to cryptocurrencies and to create a national Bitcoin reserve.

These actions could potentially pave the way for more lenient regulations and heightened interest in digital currencies.  Analysts believe that these remarks are likely to benefit Coinbase if they lead to a more supportive regulatory environment.

Technical analysis gives more insight into how Coinbase’s stock is doing. From February 2024, Coinbase’s share price has moved within a wide range. It has support at $193.60 and faces resistance around $272.90. The stock shows an ascending channel pattern. This points to higher lows and some stability in the short-term. But if it can’t stay above $224.68, it might drop to test lower support levels again. For buyers, getting past the $272.90 resistance remains a big hurdle.

Coinbase Global Inc. (COIN), closed Monday's trading session at $189.47, off by 7.3224%, on 18,734,646 volume. The average volume for the last 3 months is 4.044M and the stock's 52-week low/high is $69.63/$283.48.

HIVE Blockchain Technologies Ltd. (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, CryptoCurrencyWire, Zacks, StreetInsider, Early Bird, Marketbeat.com, StockMarketWatch, Stock Market Watch, Greenbackers, Hit and Run Candle Sticks, Barchart, smartOTC, StockOodles, StreetAuthority Daily, The Night Owl, The Online Investor, TopStockAnalysts, Wall Street Resources, WealthMakers and Schaeffer's reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

At one point, Donald Trump seemed like an unlikely advocate for cryptocurrency. He was skeptical of Bitcoin during his presidency, stating that it was “not money,” too volatile and backed by nothing substantial. He even warned that cryptocurrencies were a gateway to illegal activities.

However, Trump recently made an appearance at the largest annual cryptocurrency event in Nashville, not as a skeptic but as a prominent supporter. This marked a significant shift in his stance, coinciding with his current campaign for the presidency.

Despite his previous misgivings and the industry’s tumultuous history, Trump has now embraced the optimism and potential of the crypto world. His campaign has even started accepting Bitcoin donations, reportedly raising around $4 million this way.

Trump has also criticized the Biden administration’s regulatory actions, claiming they amount to an attack on cryptocurrency, though he hasn’t addressed the significant fraud incidents that have dented public trust in digital currencies. He has promised that, if elected, he would facilitate the operation of cryptocurrency mining companies in the U.S.

The crypto sector, in turn, has rallied around Trump. Many investors and leaders have donated substantial amounts to his campaign and related political groups. They’ve also used their online platforms to support his candidacy, providing him with a direct audience at the Bitcoin Conference, which drew around 20,000 attendees.

Trump made several promises at the conference, including the removal of Securities and Exchange Commission (SEC) Chair Gary Gensler and the establishment of a strategic national bitcoin reserve.

While Trump’s campaign hasn’t clarified what led to his change of heart regarding Bitcoin, it’s clear that he has not addressed the criticism that cryptocurrencies lack practical, everyday use beyond being speculative investments. Republican supporters have also shown support for cryptocurrency. Senator Tim Scott of South Carolina, for example, stressed during his speech at the conference that Trump is cognizant of the worries that cryptocurrency aficionados have about their financial independence.

The industry has actively engaged with Trump, educating his campaign about their policy goals and the potential voter support they could gain. Support for Trump from the crypto community has been significant. The billionaire Winklevoss twins, Cameron and Tyler, each pledged $1 million in Bitcoin to his campaign.

Cryptocurrency was also discussed during a recent fundraising tour through Silicon Valley organized by Trump’s running mate, Ohio Senator JD Vance. One of the events was hosted by David Sacks, a billionaire tech entrepreneur and vocal crypto advocate. Sacks mentioned in a podcast that business leaders, including those in the crypto space, are frustrated with the current administration’s lack of clear regulations.

The crypto industry’s involvement in politics has been growing, with significant financial support directed toward Republican candidates. Tyler Winklevoss has even suggested that opposing the crypto community could be “political suicide.”

Despite growing awareness and interest in cryptocurrency, many Americans remain cautious. According to a 2023 Pew Research poll, 75% of Americans don’t think cryptocurrencies are trustworthy or safe, even though nearly 90% of adults have heard of them.

Trump’s efforts to reach out to cryptocurrency aficionados are similar to his attempts to engage nontraditional voter bases. He spoke at the Libertarian Party’s annual conference earlier this year, arguing that the 50 million cryptocurrency owners in the U.S. should have the freedom to keep their funds. This action illustrates how the culture of the cryptocurrency ecosystem and libertarian beliefs significantly intersect.

Crypto industry players SUCH AS HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) will be following the campaigns to see what views different candidates have regarding the industry and how those views could influence future policy.

HIVE Blockchain Technologies Ltd. (HIVE), closed Monday's trading session at $2.78, off by 9.1503%, on 5,657,070 volume. The average volume for the last 3 months is 1.853M and the stock's 52-week low/high is $2.18/$5.74.

The QualityStocks Company Corner

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"), is spotlighted in the latest episode of The Bell2Bell Podcast, released by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. The episode, which featured Annovis Bio founder, president and CEO Dr. Maria Maccecchini, PhD, was recorded live from the Alzheimer's Association International Conference(R) 2024 ("AAIC").

During the episode, Maccecchini and IBN's Stuart Smith discussed the results of the company's recent phase 3 Parkinson's study of its lead drug candidate, buntanetap. Maccecchini talked about how the scientific community is reacting to the promising data and what buntanetap could mean for the future of neurodegenerative disease treatment. She also noted Annovis Bio's plans moving forward, including potential regulatory milestones and upcoming clinical trials designed to further validate the efficacy and safety of buntanetap in treating both Parkinson's and Alzheimer's diseases.

"Our phase 3 data indicate that buntanetap has the potential to significantly improve the quality of life for Parkinson's patients," said Annovis Bio founder, president and CEO Dr. Maria Maccecchini, PhD, during the episode. "Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer's and Parkinson's research, underscores the importance of our work and the promise it holds for patients."

To view the episode, visit https://ibn.fm/ynzI0

To view the full press release, visit https://ibn.fm/06kvs

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

  • Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
  • Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
  • Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
  • Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.
Recent Achievements

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Investment Considerations
  • Unique Market Position: Annovis Bio is uniquely positioned as the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins simultaneously.
  • Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients, and the recent Phase III data in PD patients further validates its broad therapeutic potential.
  • Strategic Growth Plans: With recent successful trial results, Annovis Bio is poised for future growth, supported by strong patent protections and upcoming clinical trials.
  • Significant Market Need: As the prevalence of neurodegenerative diseases continues to rise, the demand for effective treatments like buntanetap remains critical.

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Investment Considerations
  • Unique Market Position: Annovis Bio is uniquely positioned as the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins simultaneously.
  • Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients, and the recent Phase III data in PD patients further validates its broad therapeutic potential.
  • Strategic Growth Plans: With recent successful trial results, Annovis Bio is poised for future growth, supported by strong patent protections and upcoming clinical trials.
  • Significant Market Need: As the prevalence of neurodegenerative diseases continues to rise, the demand for effective treatments like buntanetap remains critical.

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

  • Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
  • Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
  • Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
  • Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Annovis Bio Inc. (NYSE: ANVS), closed Monday's trading session at $8.4, off by 3.0023%, on 256,602 volume. The average volume for the last 3 months is 37,626 and the stock's 52-week low/high is $4.53/$22.49.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"). The company is set to present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase and host 1x1 investor meetings. The company's presentation is scheduled for August 13, 2024, at 11:30 a.m. EST.

To view the live webcast, visit https://ibn.fm/uGo0W

To view the full press release, visit https://ibn.fm/DAs5q

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Monday's trading session at $4, off by 7.6212%, on 43,114 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $22.49/$.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Decentralized energy generation for specific geographic locations is growing in popularity as a solution for customers searching for climate-friendly alternatives

Environmentally conscious corporations are likewise seeking solutions that will help them meet global sustainability goals and social and governance reporting

Distributed energy solutions developer Correlate Energy Corp. is helping clients meet the challenges of the modern energy era, focusing on behind-the-meter solar infrastructure improvements, access to financing, and measurable progress in sustainable solutions

Correlate Energy is using strategic partnerships to boost its ability to provide clients with data-driven responsiveness for decarbonization, site analysis, and design proposal needs

Correlate Energy (OTCQB: CIPI), a publicly traded distributed energy-solutions company, is making a name for itself by making clean-energy adoption as easy and as seamless as possible. According to a recent article, the company is carving out a solid market share in the growing renewable energy space. The article noted that, with the global solar capacity set to reach 5.1 TW by 2028, Correlate is ideally positioned to tap this growth as it focuses on making the transition easier and more affordable by offering key benefits associated with its adoption while also encouraging profitability and overall sustainability and reducing carbon footprint.

"So far, Correlate has developed, financed and deployed over $2 billion in clean energy projects, a testament to the interest in its sustainable energy solutions," the article stated. "The company has achieved this by establishing decentralized systems, building and selling localized clean energy solutions and microgrids for industrial, commercial, and residential customers. Its approach has seen its products and services adopted throughout the United States, with notable customers including Safeway, Samsung, Cisco, Marshall Medical Center, and Tyson."

To view the full press release, visit https://ibn.fm/O2FHi

The latest Peoples' Climate Vote by the United Nations has revealed that most countries support transitioning to clean energy as quickly as possible. Titled "Accelerating an Equitable Transition: A Data-Driven Approach," the report found that a whopping 85% of countries are interested in a fast transition to renewables, indicating that the green-energy transition is a major priority for a majority of the world. Unfortunately, making this transition equitable will most likely be a massive challenge. Developing and emerging countries received less than 15% of the $1.8 trillion that was invested into developing green-energy infrastructure last year, putting them at a significant disadvantage compared to the developed economies that received most of these funds. If this trend continues, the transition to renewables will largely be limited to first-world countries such as the United States, China and several EU nations. The UN poll found that 6 out of 10 people in the most underdeveloped countries in the world are worried about the ongoing climate crisis compared to 5 out of 10 people from G20 nations. The countries most concerned with the climate crisis were Fiji at 80%, Afghanistan (78%), Mexico (77%), Turkey (77%), Paraguay (76%), the Republic of Korea (76%), Brazil (76%), Ecuador (76%), Colombia (75%) and Guatemala (74%). For-profit entities, such as Correlate Energy Corp. (OTCQB: CIPI), may offer pointers regarding how equity can be brought to the energy-transition movement through the use of cost-effective green-energy generation systems that are decentralized.

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Monday's trading session at $0.30977, off by 6.1303%, on 112 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.05/$2.35.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA"). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and autism spectrum disorder ("ASD"). The process includes having a Type C meeting with the FDA, and then incorporating the outcomes of that meeting, which is a key opportunity for PaxMedica to demonstrate the therapeutic potential and public health benefits of PAX-101.

"PaxMedica's primary mission is to address the unmet medical needs in ASD," the article states. "The company is developing PAX-101 for ASD, with a completed phase 2B study showing promising results. Additionally, PAX-102, an intranasal formulation of suramin, is under evaluation for ASD and other neurodevelopmental conditions. The company's commitment extends to exploring selective APTs that target specific purinergic receptors, potentially offering enhanced therapeutic benefits."

To view the full article, visit https://ibn.fm/oJcao

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Monday's trading session at $0.23015, off by 4.9556%, on 20,610 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.20/$11.8796.

Recent News

Energy and Water Development Corp. (OTCQB: EAWD)

The QualityStocks Daily Newsletter would like to spotlightFathom Energy and Water Development Corp. (OTCQB: EAWD) .

Energy and Water Development (OTCQB: EAWD), a green-tech engineering solutions company focused on delivering water and energy to extreme environments, offers some independence from groundwater and other traditional sources for fresh water. That independence can make a difference within a framework created by existing issues associated with climate change and its impact on water access. A recent article notes that the company, which has experience in building water and energy systems out of already existing and proven technologies, is aware of the challenge of climate change and is looking to address it.

Through its innovative, off-grid solution that utilizes solar power and other available energy sources to pull water directly from the atmosphere, the company is making clean water accessible, especially to endangered populations. "We know that water scarcity is a critical and growing issue that does not discriminate," said Energy and Water Development CEO Irma Velazquez in the article. "Everyone, anywhere, is entitled to clean, abundant drinking water and our improved off-grid atmosphere water generation systems can help communities provide an unlimited source of fresh water without drawing any power from the grid, even in the most severely drought-stricken areas."

To view the full press release, visit https://ibn.fm/E2r5a

Energy and Water Development Corp. (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.

Products

In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (AWG) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

Energy and Water Development Corp. (OTCQB: EAWD), closed Monday's trading session at $0.04, off by 11.1111%, on 65,749 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0159/$0.12.

Recent News

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel's sprawling Gochager Lake Project covers 22,000+ hectares in the metal rich Trans-Hudson Corridor in Saskatchewan, Canada

Located on the west side of the property about 10 kilometers from the Gochager deposit, the Mal Lake tenure hasn't been explored since 1967; Fathom just re-evaluated available historic drill core

The findings suggest similarities in nickel tenor, nickel-to-copper ratio, and even the source magma type between Mal Lake and Gochager Lake, hinting at a potential magmatic conduit system

Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is pointing towards a bright future for its Gochager Lake property, thanks to recent core reviews at the nearby Mal Lake nickel occurrence. A recent press release highlights the exciting potential of the newly acquired Mal Lake tenure and its possible connection to the Gochager Lake deposit, both of which are part of Fathom's more than 22,000-hectare Gochager Lake project in the Trans-Hudson Corridor in Saskatchewan.

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Monday's trading session at $0.0358, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0222/$0.2588.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading entity in the cannabis and agricultural technology sectors, is focused on solidifying its position in the growing cannabis market. According to a recent article, the global cannabis market, which reached an estimated $27.7 billion in 2022, is forecast to total $82.3 billion in 2027. MedCana is working on becoming the world's premier resource for pharmaceutical cannabis products and playing a key role in that growing space. The company is currently involved in building technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world. The article noted that recognition of cannabis's therapeutic properties and its potential to treat various medical conditions along with changing attitudes toward cannabis use and increasing consumer acceptance are key drivers for growth. In addition, increased investments in cannabis-based medications from pharmaceutical companies are contributing to market expansion. "These factors all point to a promising cannabis sector moving forward, with MedCana committed to doing the work necessary to become a leader in the space," the article states, noting that the company is a global infrastructure and holding company in the cannabis industry. MedCana has five divisions focused on pharmaceutical cannabis production, as well a software division focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology division has added to its portfolio of holdings. To view the full article, visit https://ibn.fm/q1hbs

A recent study indicates that the availability of medical cannabis might lead to increased parenting time by improving patients' overall health. Published in the "Journal of Applied Economics," the research notes that medical cannabis legalization enhances sleep and reduces inactivity, aligning with its health benefits. According to the study, the legalization of medical cannabis can have a positive effect on a child's development by allowing parents to spend more time with their kids, particularly if they are younger than six years old, a critical age for parental involvement. These advantages, however, are dependent on parents not abusing cannabis. The study found no evidence that medical cannabis legalization negatively impacted productive time use, such as home production and market work, or led to increased tobacco or drug use. However, a key drawback of the study is the lack of individual-level cannabis use data in the ATUS. "Moreover, it is imperative to interpret the results in light of the USA's global leadership in the consumption of opioid analgesics, which could serve as a viable alternative to medical cannabis," the authors noted. The findings of this study are likely to provide some additional validation for numerous companies such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) that are engaged in commercializing medical marijuana products that target different health conditions, such as chronic pain.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Monday's trading session at $0.025, off by 7.4074%, on 51,139 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

ECGI Holdings Inc. (OTC: ECGI)

The QualityStocks Daily Newsletter would like to spotlight ECGI Holdings Inc. (OTC: ECGI).

ECGI Holdings (OTC: ECGI), a diversified holding company focusing on viticulture, luxury fashion and equestrian markets, is eyeing segments of the luxury goods market as an opportunity to generate significant annual revenues. According to a recent article, ECGI believes the luxury apparel and accessories segments, which excludes broader categories such as watches, jewelry and beauty, make up about 50% of the luxury market in the United States and maybe even worldwide. The article notes that the luxury apparel and accessories segments are valued at approximately $37 billion in the U.S.; that could translate to revenues of between $370 million and $1.85 billion for companies that are able to claim a market share of 1–5%. "The luxury equestrian market offers a path to the much greater overall luxury and overall equestrian markets, where significant revenues are available without having to become a major player as would be the case in a smaller market," the article stated.

To view the full article, visit https://ibn.fm/xtRpl

ECGI Holdings Inc. (OTC: ECGI) is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The company owns and manages a five-acre vineyard in Lake County, California, specializing in cultivating the Petite Sirah varietal, known for its bold and rich character, aligning with the growing demand for unique and high-quality wine experiences.

In the fashion sector, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer of luxury equestrian tack, apparel and accessories. This unique blend of wine and fashion investments reflects ECGI Holdings’ commitment to delivering sophistication and innovation across diverse markets, positioning the company as a distinctive player in the intersection of technology, viticulture and luxury lifestyle.

Moving forward, ECGI Holdings is focused on identifying and capitalizing on growth opportunities that align with the company’s business objectives and continuing to improve its financial structure. In 2024, ECGI Holdings was approved by Evolve — a distinguished name in vacation rental management. This partnership will transform the company’s 40-acre Lake County property into a luxurious short-term rental destination aptly named Vintner’s Caldera Ranch.

ECGI Holdings is excited about the possibilities that Vintner’s Caldera Ranch creates for shareholders and looks forward to further developments poised to unlock the value of other underutilized assets. The company believes that it is laying a solid foundation for sustained success and profitability in the years to come.

ECGI Holdings is headquartered in Irvine, California.

Operational Philosophy

ECGI Holdings has embarked on an ambitious new vision and strategic direction to build and nurture luxury brands that resonate with its core values and market aspirations. Its joint venture with Pacific Saddlery epitomizes ECGI Holdings’ strategic shift toward luxury branding, leveraging Pacific Saddlery’s tangible and established market presence in equestrian products.

This transition will also allow ECGI Holdings to explore new pathways to monetize its underutilized assets, including the company’s vineyard. A key highlight of the company’s future outlook is the debut of Pacific Saddlery’s new mobile retail boutique at specific equestrian events in 2024. This innovative venture represents a significant step in ECGI Holdings’ strategy to enhance brand visibility and engage directly with the company’s target market.

In addition, the Vintner’s Caldera Ranch development marks a significant step in advancing the company’s strategy to revitalize and leverage underutilized assets. Vintner’s Caldera Ranch is set against the backdrop of Lake County’s breathtaking scenery, offering an exclusive getaway experience that blends natural beauty with luxury. Choosing Evolve is a strategic move to ensure that Vintner’s Caldera Ranch not only meets but exceeds the high standards of service that luxury guests expect.

Evolve’s expertise in maximizing rental potential and delivering exceptional guest experiences is crucial to the company’s vision of making Vintner’s Caldera Ranch a preferred choice for discerning travelers. With this venture, ECGI Holdings is not only expanding its footprint within the luxury rental marketplace, but also contributing to the local economy and enhancing the appeal of Lake County as a tourist destination.

The company’s focus remains steadfast on strategic growth, operational excellence and customer satisfaction.

Market Outlook

A report from Grand View Research, a global market research and consulting company, estimated the value of the worldwide luxury brands market at $366.23 billion in 2023 and projects the market to grow to a value of $580.43 billion by 2030, achieving a CAGR of 6.8% over the forecast period.

Rising disposable income and wealth in various regions of the world, particularly in emerging markets such as China and India, have propelled the growth of the market, according to the report.

Younger consumers, such as millennials and Generation Z, are increasingly entering the luxury market, driving demand for more contemporary and experiential luxury offerings. The rise of social media and influencer marketing has greatly impacted the visibility and desirability of luxury products, the report states.

Management Team

Jamie Steigerwald is CEO of ECGI Holdings, Inc. He is a successful entrepreneur with over 30 years of experience. Most recently, he was COO of Sugarmade Inc. (OTC: SGMD), a California cannabis real estate, cultivation, manufacturing and services company. He is the owner of SwiftLead, an Orange County web marketing, design and development company. He previously was COO for First USA Home Loans, a retail mortgage lender, and co-founder and President of SwiftLead Software, a mortgage lead tracking system.

Nick Collins is CEO at Pacific Saddlery. He brings over 25 years of expertise in equestrian luxury goods. He previously founded Rolling Meadows and created the Allon Equestrian and Renard et Cheval apparel brands. He was instrumental in creating and launching Kaval.com, an online equestrian apparel and accessories site.

ECGI Holdings Inc. (OTC: ECGI), closed Monday's trading session at $0.0023, off by 0.862069%, on 63,291 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0016/$0.0149.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Upstream, a MERJ Exchange stock market and global trading app, is reporting on the first week of trading for spot Ethereum exchange-traded funds ("ETFs"). According to the article, spot Ethereum ETFs began trading on July 23, 2024; the ETFs were offered by entities such as BlackRock, Fidelity, 21Shares, Bitwise, Franklin Templeton, VanEck and Invesco Galaxy, which also offer spot Bitcoin ETFs. Spot Ethereum ETFs started strong with more than $1 billion in trade volume on the first day, representing 23% of the volume seen by Bitcoin ETFs on their launch.

Upstream noted that Ethereum ETFs, which are similar to traditional ETFs and Bitcoin ETFs, track the price of Ethereum, which is the world's second-largest cryptocurrency, without investors directly owning the cryptocurrency. This approach provides a way for investors who are more familiar with regulated U.S. exchanges to participate in the crypto market.

"While the U.S. Ether ETF launches are an exciting milestone for the crypto and greater blockchain community, hurdles like account minimums, market hours and phone regulatory hurdles may still be limiting international participation," said the Upstream article. "This is where Upstream believes we can make a difference. Upstream, a MERJ Exchange market and global stock trading app, works to make it easier for international investors to access U.S. and international equities. Upstream is actively accepting applications for both ether and bitcoin ETFs to list."

To view the full article, visit https://ibn.fm/6k5Hm

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Monday's trading session at $0.2487, up 17.8673%, on 17,030,900 volume. The average volume for the last 3 months is 3.482M and the stock's 52-week low/high is $0.1524/$1.13.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Monday's trading session at $0.033, up 3.125%, on 24,099 volume. The average volume for the last 3 months is 477,167 and the stock's 52-week low/high is $0.0271/$0.07.

Recent News

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Monday's trading session at $0.0955, up 4.7149%, on 43,953 volume. The average volume for the last 3 months is 138,223 and the stock's 52-week low/high is $0.0682/$1.339.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.